Karyopharm Therapeutics Statistics Share Statistics Karyopharm Therapeutics has 8.67M
shares outstanding. The number of shares has increased by 2.56%
in one year.
Shares Outstanding 8.67M Shares Change (YoY) 2.56% Shares Change (QoQ) 0.36% Owned by Institutions (%) 46.91% Shares Floating 7.93M Failed to Deliver (FTD) Shares 4,284 FTD / Avg. Volume 2.44%
Short Selling Information The latest short interest is 2.2M, so 25.42% of the outstanding
shares have been sold short.
Short Interest 2.2M Short % of Shares Out 25.42% Short % of Float 25.61% Short Ratio (days to cover) 30.17
Valuation Ratios The PE ratio is -1.08 and the forward
PE ratio is -0.81.
Karyopharm Therapeutics's PEG ratio is
0.02.
PE Ratio -1.08 Forward PE -0.81 PS Ratio 0.57 Forward PS 0.3 PB Ratio -0.44 P/FCF Ratio -0.65 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Karyopharm Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.7,
with a Debt / Equity ratio of -1.05.
Current Ratio 1.7 Quick Ratio 1.64 Debt / Equity -1.05 Debt / EBITDA -5.04 Debt / FCF -1.52 Interest Coverage -3.19
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $520.56K Profits Per Employee $-273.91K Employee Count 279 Asset Turnover 0.88 Inventory Turnover 1.27
Taxes Income Tax 57K Effective Tax Rate -0.07%
Stock Price Statistics The stock price has increased by -52.07% in the
last 52 weeks. The beta is 0.34, so Karyopharm Therapeutics's
price volatility has been higher than the market average.
Beta 0.34 52-Week Price Change -52.07% 50-Day Moving Average 5.77 200-Day Moving Average 6.44 Relative Strength Index (RSI) 51.4 Average Volume (20 Days) 175,777
Income Statement In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M
and earned -76.42M
in profits. Earnings per share was -9.41.
Revenue 145.24M Gross Profit 139.23M Operating Income -119.44M Net Income -76.42M EBITDA -38.6M EBIT -38.94M Earnings Per Share (EPS) -9.41
Full Income Statement Balance Sheet The company has 62.48M in cash and 194.52M in
debt, giving a net cash position of -132.05M.
Cash & Cash Equivalents 62.48M Total Debt 194.52M Net Cash -132.05M Retained Earnings -1.56B Total Assets 104.88M Working Capital -1.35M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -127.49M
and capital expenditures -142K, giving a free cash flow of -127.63M.
Operating Cash Flow -127.49M Capital Expenditures -142K Free Cash Flow -127.63M FCF Per Share -15.71
Full Cash Flow Statement Margins Gross margin is 95.86%, with operating and profit margins of -82.24% and -52.62%.
Gross Margin 95.86% Operating Margin -82.24% Pretax Margin -52.58% Profit Margin -52.62% EBITDA Margin -26.58% EBIT Margin -82.24% FCF Margin -87.88%
Dividends & Yields KPTI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for KPTI is $29,
which is 354.5% higher than the current price. The consensus rating is "Buy".
Price Target $29 Price Target Difference 354.5% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 26, 2025. It was a
backward
split with a ratio of 1:15.
Last Split Date Feb 26, 2025 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -22.73 Piotroski F-Score 4
